Individualizirovannaya antitromboticheskaya terapiya pri fibrillyatsii predserdiy
- 作者: Ashikhmin Y.I1, Shchekochikhin D.Y.1
-
隶属关系:
- 期: 编号 18 (2013)
- 页面: 119-123
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/282683
- ID: 282683
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
Until recently, vitamin K antagonist warfarin was a main drug for systemic anticoagulation in atrial fibrillation (AF). The emergence of new anticoagulants - dabigatran, rivaroxaban and apixaban - greatly expanded the approaches to the prevention of stroke in patients with AF. This article highlights the practical aspects of selection of antithrombotic therapy in AF from a perspective of efficacy and safety.
全文:
参考
- focused update of the ESC Guidelines for the management of atrial brillation. Eur Heart J 2012;33:2719–47.
- Connolly S, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364(9):806–17.
- Connolly S, Ezekowitz M, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009;361:1139–51.
- Eikelboom J, Weitz J. Dabigatran and risk of myocardial infarction. Nat Rev Cardiol 2012; 9:260–62.
- Favaloro E, Lippi G. The new oral anticoagulants and the future of haemostasis laboratory testing. Biochem Med 2012;22(3):329–41.
- Go A, Hylek E, Phillips K, et al. Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation. Circulation 2000;102(1):11–3.
- Granger C, Alexander J, McMurray J, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–92.
- Hart R, Pearce L, Aguilar M. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146(12):857–67.
- Kearon C, Ginsberg J, Kovacs M, et al. Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism. N Engl J Med 2003; 349:631-39.
- Mantha S, Cabral K, Ansell J. New avenues for anticoagulation in atrial fibrillation. Clin Pharmacol Ther 2013;93(1):68-77.
- Nagarakanti R, Ezekowitz M, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;1 23(2):131-36.
- Patel M, Hellkamp A, Lokhnygina Y, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial. J Am Coll Cardiol 2013;61(6): 651-58.
- Patel M, Mahaffey K, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
- Piccini J, Stevens S, Lokhnygina Y, et al. Outcomes Following Cardioversion and Atrial Fibrillation Ablation in Patients Treated with Rivaroxaban and Warfarin in the ROCKET AF Trial. J Am Coll Cardiol 2013;61(19):1998-2006.
- Reddy V, Doshi S, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation. Circulation 2013;127(6):720-29.
- Roskell N, Samuel M, Noack H, et al. Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies. Europace 2013;15(6):787-97.
- Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47(1):47-59.
- Eikelboom J, Connolly S, Brueckmann M, et al. Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. N Engl J Med 2013 doi: 10.1056/NEJMoa1300615.
补充文件
